Tags

Type your tag names separated by a space and hit enter

Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
BMJ. 2012 Jul 12; 345:e4445.BMJ

Abstract

OBJECTIVE

To investigate whether a single optimal vaccination strategy exists across countries to deal with a future influenza pandemic by comparing the cost effectiveness of different strategies in various pandemic scenarios for three European countries.

DESIGN

Economic and epidemic modelling study.

SETTINGS

General populations in Germany, the Netherlands, and the United Kingdom.

DATA SOURCES

Country specific patterns of social contact and demographic data.

MODEL

An age structured susceptible-exposed-infected-recovered transmission model that describes how an influenza A virus will spread in the populations of Germany, the Netherlands, and the United Kingdom.

INTERVENTIONS

Comparison of four vaccination strategies: no vaccination, blanket vaccination, vaccination of elderly people (≥ 65 years), and vaccination of high transmitters (5-19 years). The four strategies were evaluated for scenarios in which a vaccine became available early or at the peak of the pandemic, and in which either everyone was initially susceptible or older age groups had pre-existing immunity.

MAIN OUTCOME MEASURE

Cost per quality adjusted life years (QALYs) gained.

RESULTS

All vaccination strategies were cost effective (incremental cost per QALY gained, comparing intervention with non-intervention). In scenarios where the vaccine became available at the peak of the pandemic and there was pre-existing immunity among elderly people the incremental cost effectiveness ratios for vaccinating high transmitters were €7325 (£5815; $10,470) per QALY gained for Germany, €10,216 per QALY gained for the Netherlands, and €7280 per QALY gained for the United Kingdom. The most cost effective strategy not only differed across the pandemic scenarios but also between countries. Specifically, when the vaccine was available early in the pandemic and there was no pre-existing immunity, in Germany it would be most cost effective to vaccinate elderly people (€940 per QALY gained), whereas it would be most cost effective to vaccinate high transmitters in both the Netherlands (€525 per QALY gained) and the United Kingdom (€163 per QALY gained). This difference in optimal strategies was due to differences in the demographic characteristics of the countries: Germany has a significantly higher proportion of elderly people compared with the Netherlands and the United Kingdom.

CONCLUSIONS

No single vaccination strategy was most cost effective across countries. With aging populations, pre-existing immunity in particular could be of crucial importance for the cost effectiveness of options to mitigate a future influenza pandemic.

Authors+Show Affiliations

Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, Netherlands. anna.lugner@rivm.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22791791

Citation

Lugnér, Anna K., et al. "Cost Effectiveness of Vaccination Against Pandemic Influenza in European Countries: Mathematical Modelling Analysis." BMJ (Clinical Research Ed.), vol. 345, 2012, pp. e4445.
Lugnér AK, van Boven M, de Vries R, et al. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ. 2012;345:e4445.
Lugnér, A. K., van Boven, M., de Vries, R., Postma, M. J., & Wallinga, J. (2012). Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ (Clinical Research Ed.), 345, e4445. https://doi.org/10.1136/bmj.e4445
Lugnér AK, et al. Cost Effectiveness of Vaccination Against Pandemic Influenza in European Countries: Mathematical Modelling Analysis. BMJ. 2012 Jul 12;345:e4445. PubMed PMID: 22791791.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. AU - Lugnér,Anna K, AU - van Boven,Michiel, AU - de Vries,Robin, AU - Postma,Maarten J, AU - Wallinga,Jacco, Y1 - 2012/07/12/ PY - 2012/7/14/entrez PY - 2012/7/14/pubmed PY - 2012/9/21/medline SP - e4445 EP - e4445 JF - BMJ (Clinical research ed.) JO - BMJ VL - 345 N2 - OBJECTIVE: To investigate whether a single optimal vaccination strategy exists across countries to deal with a future influenza pandemic by comparing the cost effectiveness of different strategies in various pandemic scenarios for three European countries. DESIGN: Economic and epidemic modelling study. SETTINGS: General populations in Germany, the Netherlands, and the United Kingdom. DATA SOURCES: Country specific patterns of social contact and demographic data. MODEL: An age structured susceptible-exposed-infected-recovered transmission model that describes how an influenza A virus will spread in the populations of Germany, the Netherlands, and the United Kingdom. INTERVENTIONS: Comparison of four vaccination strategies: no vaccination, blanket vaccination, vaccination of elderly people (≥ 65 years), and vaccination of high transmitters (5-19 years). The four strategies were evaluated for scenarios in which a vaccine became available early or at the peak of the pandemic, and in which either everyone was initially susceptible or older age groups had pre-existing immunity. MAIN OUTCOME MEASURE: Cost per quality adjusted life years (QALYs) gained. RESULTS: All vaccination strategies were cost effective (incremental cost per QALY gained, comparing intervention with non-intervention). In scenarios where the vaccine became available at the peak of the pandemic and there was pre-existing immunity among elderly people the incremental cost effectiveness ratios for vaccinating high transmitters were €7325 (£5815; $10,470) per QALY gained for Germany, €10,216 per QALY gained for the Netherlands, and €7280 per QALY gained for the United Kingdom. The most cost effective strategy not only differed across the pandemic scenarios but also between countries. Specifically, when the vaccine was available early in the pandemic and there was no pre-existing immunity, in Germany it would be most cost effective to vaccinate elderly people (€940 per QALY gained), whereas it would be most cost effective to vaccinate high transmitters in both the Netherlands (€525 per QALY gained) and the United Kingdom (€163 per QALY gained). This difference in optimal strategies was due to differences in the demographic characteristics of the countries: Germany has a significantly higher proportion of elderly people compared with the Netherlands and the United Kingdom. CONCLUSIONS: No single vaccination strategy was most cost effective across countries. With aging populations, pre-existing immunity in particular could be of crucial importance for the cost effectiveness of options to mitigate a future influenza pandemic. SN - 1756-1833 UR - https://www.unboundmedicine.com/medline/citation/22791791/Cost_effectiveness_of_vaccination_against_pandemic_influenza_in_European_countries:_mathematical_modelling_analysis_ L2 - https://www.bmj.com/lookup/pmidlookup?view=long&pmid=22791791 DB - PRIME DP - Unbound Medicine ER -